| P50 | author | Miao Wang | Q51155711 |
| P2093 | author name string | Garret A FitzGerald | |
| P2860 | cites work | Identification of human prostaglandin E synthase: a microsomal, glutathione-dependent, inducible enzyme, constituting a potential novel drug target | Q22010153 |
| | Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis | Q22254717 |
| | Structural basis for induced formation of the inflammatory mediator prostaglandin E2. | Q24321522 |
| | Cardiomyocyte cyclooxygenase-2 influences cardiac rhythm and function | Q24657715 |
| | Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase | Q24678462 |
| | Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo | Q28188254 |
| | Role of prostacyclin in the cardiovascular response to thromboxane A2 | Q28192832 |
| | Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling | Q28198809 |
| | Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 |
| | Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study | Q28219713 |
| | Activation of the murine EP3 receptor for PGE2 inhibits cAMP production and promotes platelet aggregation | Q28359873 |
| | Inhibition of prostaglandin E2 synthesis in abdominal aortic aneurysms: implications for smooth muscle cell viability, inflammatory processes, and the expansion of abdominal aortic aneurysms | Q28368326 |
| | Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II | Q28508911 |
| | Microsomal Prostaglandin E Synthase-1 Is a Major Terminal Synthase That Is Selectively Up-Regulated During Cyclooxygenase-2-Dependent Prostaglandin E2 Production in the Rat Adjuvant-Induced Arthritis Model | Q28565601 |
| | Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention | Q29620087 |
| | Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function | Q30477135 |
| | Deletion of microsomal prostaglandin E synthase-1 does not alter ozone-induced airway hyper-responsiveness | Q30495751 |
| | Microsomal prostaglandin e2 synthase-1 modulates the response to vascular injury | Q30557273 |
| | Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney | Q33201634 |
| | Role of microsomal prostaglandin E synthase 1 in the kidney. | Q51756533 |
| | Activated forms of MMP2 and MMP9 in abdominal aortic aneurysms | Q71218618 |
| | Microsomal prostaglandin E2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction | Q80889077 |
| | Predominance of cyclooxygenase 1 over cyclooxygenase 2 in the generation of proinflammatory prostaglandins in autoantibody-driven K/BxN serum-transfer arthritis | Q81158306 |
| | Abdominal aortic aneurysm | Q81706496 |
| | Human glutathione dependent prostaglandin E synthase: gene structure and regulation | Q33897775 |
| | Human microsomal prostaglandin E synthase-1: purification, functional characterization, and projection structure determination. | Q34188046 |
| | Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities | Q34245387 |
| | Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis | Q34247727 |
| | Lack of EP4 receptors on bone marrow-derived cells enhances inflammation in atherosclerotic lesions | Q34410269 |
| | Abdominal aortic aneurysm: pathogenesis and implications for management | Q34566262 |
| | Membrane prostaglandin E synthase-1: a novel therapeutic target | Q34690079 |
| | Lack of microsomal prostaglandin E synthase-1 reduces cardiac function following angiotensin II infusion | Q34720276 |
| | Cyclooxygenase-2 and inflammation in atherosclerosis | Q35737703 |
| | Prostaglandin E synthase: a novel drug target for inflammation and cancer | Q36419635 |
| | Is mPGES-1 a promising target for pain therapy? | Q36525368 |
| | Macrophage EP4 deficiency increases apoptosis and suppresses early atherosclerosis | Q37039326 |
| | Microsomal prostaglandin E synthase 1 determines tumor growth in vivo of prostate and lung cancer cells | Q37401875 |
| | Targeted lipidomics reveals mPGES-1-PGE2 as a therapeutic target for multiple sclerosis | Q37463199 |
| | Roles of thromboxane A(2) and prostacyclin in the development of atherosclerosis in apoE-deficient mice | Q37511097 |
| | Emotion recollected in tranquility: lessons learned from the COX-2 saga. | Q37670839 |
| | Microsomal prostaglandin E synthase-1 and 5-lipoxygenase: potential drug targets in cancer | Q37760267 |
| | Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice | Q38600691 |
| | MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation | Q39318823 |
| | Anti-inflammatory role of microsomal prostaglandin E synthase-1 in a model of neuroinflammation. | Q41975871 |
| | Identification of key residues determining species differences in inhibitor binding of microsomal prostaglandin E synthase-1 | Q42427981 |
| | Deletion of microsomal prostaglandin E synthase-1 increases sensitivity to salt loading and angiotensin II infusion | Q42503934 |
| | Microsomal prostaglandin E synthase-1 deficiency is associated with elevated peroxisome proliferator-activated receptor gamma: regulation by prostaglandin E2 via the phosphatidylinositol 3-kinase and Akt pathway | Q42506028 |
| | Do COX-2 inhibitors raise blood pressure more than nonselective NSAIDs and placebo? An updated meta-analysis | Q43248977 |
| | 15-deoxy-delta 12,14-prostaglandin J2 induces heme oxygenase-1 gene expression in a reactive oxygen species-dependent manner in human lymphocytes | Q44801463 |
| | Reduced pain hypersensitivity and inflammation in mice lacking microsomal prostaglandin e synthase-1. | Q44894446 |
| | COX-2-derived prostacyclin confers atheroprotection on female mice | Q45154810 |
| | Prostacyclin attenuates oxidative damage of myocytes by opening mitochondrial ATP-sensitive K+ channels via the EP3 receptor | Q45190178 |
| | Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice | Q45197562 |
| | Celecoxib, a selective cyclooxygenase-2 inhibitor, decreases monocyte chemoattractant protein-1 expression and neointimal hyperplasia in the rabbit atherosclerotic balloon injury model | Q45197823 |
| | Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. | Q45227725 |
| | Comparison of microsomal prostaglandin E synthase-1 deletion and COX-2 inhibition in acute cardiac ischemia in mice. | Q45950228 |
| | The effects of microsomal prostaglandin E synthase-1 deletion in acute cardiac ischemia in mice. | Q45970253 |
| | Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population | Q46257782 |
| | Homo-timeric structural model of human microsomal prostaglandin E synthase-1 and characterization of its substrate/inhibitor binding interactions | Q46382445 |
| | COX-2-derived prostacyclin modulates vascular remodeling. | Q46499852 |
| | Genetic deletion of mPGES-1 suppresses intestinal tumorigenesis | Q46616197 |
| | Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin II-induced abdominal aortic aneurysm formation. | Q46745011 |
| | Selective cyclooxygenase-2 inhibition with celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in mice | Q46973329 |
| | Prostaglandin E synthases in zebrafish | Q48161389 |
| P433 | issue | 6 | |
| P921 | main subject | prostaglandin E2 | Q416554 |
| P304 | page(s) | 189-195 | |
| P577 | publication date | 2010-08-01 | |
| P1433 | published in | Trends in Cardiovascular Medicine | Q1850265 |
| P1476 | title | Cardiovascular biology of microsomal prostaglandin E synthase-1 | |
| P478 | volume | 20 | |